Lindsay P. Cameron

Lindsay P. Cameron

Auto-generated profile, based on publicly available information

Lindsay P. Cameron

Nancy Pritzker Laboratory, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2023 in Science
Verified
Journal Article
Closed access
MVMaxemiliano V. Vargas
Maxemiliano V. Vargas
LDLee E. Dunlap
Lee E. Dunlap
CDChunyang Dong
Chunyang Dong
SCSamuel J. Carter
Samuel J. Carter
RTRobert J. Tombari
Robert J. Tombari
DODavid E. Olson
David E. Olson
Decreased dendritic spine density in the cortex is a hallmark of several neuropsychiatric diseases, and the ability to promote cortical neuron growth has been hypothesized to underlie the rapid and sustained therapeutic effects of psychedelics. Activation of 5-hydroxytryptamine (serotonin) 2A receptors (5-HT2ARs) is essential for psychedelic-induced cortical plasticity, but it is currently unclear why some 5-HT2AR agonists promote neuroplasticity, whereas others do not. We used molecular and genetic tools to demonstrate that intracellular 5-HT2ARs mediate the plasticity-promoting properties of psychedelics; these results explain why serotonin does not engage similar plasticity mechanisms. This work emphasizes the role of location bias in 5-HT2AR signaling, identifies intracellular 5-HT2ARs as a therapeutic target, and raises the intriguing possibility that serotonin might not be the endogenous ligand for intracellular 5-HT2ARs in the cortex.

9 December 2020 in Nature
Verified
Journal Article
Closed access
PDF file
LCLindsay P. Cameron
Lindsay P. Cameron
RTRobert J. Tombari
Robert J. Tombari
JLJu Lu
Ju Lu
APAlexander J. Pell
Alexander J. Pell
ZHZefan Q. Hurley
Zefan Q. Hurley
DODavid E. Olson
David E. Olson

1 December 2020 in Cell
Verified
Journal Article
Closed access
EUElizabeth K. Unger
Elizabeth K. Unger
JKJacob P. Keller
Jacob P. Keller
MAMichael Altermatt
Michael Altermatt
RLRuqiang Liang
Ruqiang Liang
AMAya Matsui
Aya Matsui
LTLin Tian
Lin Tian

23 January 2020 in Journal of Psychoactive Drugs
Verified
Journal Article
Closed access
LCLindsay P. Cameron
Lindsay P. Cameron
ANAngela Nazarian
Angela Nazarian
DODavid E. Olson
David E. Olson
Anecdotal reports suggest that the administration of sub-hallucinogenic doses of psychedelic compounds on a chronic, intermittent schedule – a practice known as psychedelic microdosing – is becoming increasingly popular among young adults due to its purported ability to reduce symptoms of depression and anxiety while improving cognitive function and promoting social interaction. Using an anonymous online survey, we collected data from 2347 people to 1) assess the prevalence of psychedelic microdosing and characterize the demographics of microdosers, 2) determine whether microdosers associate the practice with changes in mood, cognitive function, social interaction, or physiology, and 3) investigate frequent motives for discontinuing the practice. Fifty-nine percent of respondents (NT = 2183) reported familiarity with the concept of psychedelic microdosing, with 17% (383 respondents, NT = 2200) having engaged in this practice. Microdosers attributed psychedelic microdosing with improving their mood, decreasing their anxiety, and enhancing their memory, attention, and sociability. The most frequently cited reasons for quitting microdosing (NT = 243) were the risks associated with taking an illegal substance (24.28%) and the difficulty of obtaining psychedelic compounds (22.63%). Overall, our findings suggest that psychedelic microdosing is relatively common and is subjectively associated with a broad spectrum of socio-affective, cognitive, and physical outcomes.

4 August 2025 in Nature Neuroscience
Verified
Journal Article
Closed access
IAIsak K. Aarrestad
Isak K. Aarrestad
LCLindsay P. Cameron
Lindsay P. Cameron
EFEthan M. Fenton
Ethan M. Fenton
ACAusten B. Casey
Austen B. Casey
DRDaniel R. Rijsketic
Daniel R. Rijsketic
DODavid E. Olson
David E. Olson

16 August 2021 in Neuropsychopharmacology
Verified
Journal Article
Closed access
LCLindsay P. Cameron
Lindsay P. Cameron
DODavid E. Olson
David E. Olson